With the 2026 legislative session now underway in Hawai’i, the American Cancer Society Cancer Action Network (ACS CAN) is leading efforts to work with lawmakers on several initiatives which include defending Medicaid and expanding access to screenings for colorectal cancer for the state’s most vu
Ahead of Mills' State of the State address, ACS CAN Calls Attention to Medicaid, Biomarker Testing and Medical Debt
A new ACS CAN study released in the Journal of the American Medical Association (JAMA) finds many patients aren’t made aware of the importance of pharmacogenomic (PGx) testing. A form of biomarker testing, PGx testing examines how variations in a patient’s inherited genes may impact how they respond to different drugs and can improve the effectiveness of treatment and reduce the risk of adverse drug reactions.
Massachusetts cancer survivors and caregivers urge lawmakers to support legislation that will increase access to precision medicine and patient navigation for all communities.
Expanding access to this form of precision medicine will help more people in Connecticut get the right treatment at the right time.
Leading public health group urges Senate and Gov. Lamont to follow suit in ensuring biomarker testing can benefit more Connecticut patients
Leading public health group urges Senate and Gov. Lamont to follow suit in ensuring biomarker testing can benefit more Connecticut patients
Maryland state lawmakers have released details on the agreed upon 2025-26 budget—the contents of which are a mixed bag in the fight against cancer. While the state made sound investments in cancer research and protected Medicaid recipients’ ability to access biomarker testing, it missed an opportunity to save the lives and lungs of Maryland’s youth by cutting funding for the state’s tobacco prevention and cessation programs.
North Carolina lawmakers have taken a critical step in efforts to reduce the cancer burden by introducing House Bill 567.